SuperworthHarvard Bioscience market cap HBIO
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $37.5M
- Highest close in our data
- $344.9M
- Aug 2021
Harvard Bioscience is worth $37.5M at the close on Oct 23, 2026, at $8.23 a share.
That is up 106% over the last year and down 88% over five years.
Its highest close in our data was $344.9M in Aug 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $37.5M | $19.3M | $38M | +20% |
| 2025 | $31.3M | $13.9M | $93.3M | −64% |
| 2024 | $86.4M | $86.4M | $209.2M | −62% |
| 2023 | $228.4M | $109.1M | $259.9M | +98% |
| 2022 | $115.4M | $93.3M | $271.8M | −60% |
| 2021 | $287.7M | $164.5M | $344.9M | +72% |
| 2020 | $167.2M | $57.5M | $175.4M | +49% |
| 2019 | $111.9M | $70.5M | $172.9M | −1% |
| 2018 | $113M | $113M | $235.9M | −2% |
| 2017 | $115.1M | $81.3M | $130.6M | +10% |
| 2016 | $104.8M | $80.6M | $124.4M | −11% |
| 2015 | $117.8M | $99.7M | $218.6M | −29% |
| 2014 | $166.6M | $123.4M | $166.6M | +10% |
| 2013 | $151.9M | $96.3M | $157.2M | +63% |
| 2012 | $93.1M | $78.5M | $97M | +10% |
| 2011 | $84.4M | $84.4M | $104.8M | n/a |
Against its peers
Companies in Healthcare nearest Harvard Bioscience's size, closest first, today.
| Company | Market cap |
|---|---|
| HBIOHarvard Bioscience | $37.5M |
| NEPHNephros | $38.3M |
| ATNMActinium Pharmaceuticals | $47.8M |
| APTAlpha Pro Tech | $56.7M |
| SPROSpero Therapeutics | $64.6M |
| LFVNLifevantage | $73.4M |
| ICCCImmucell | $93.1M |
| KEQUKewaunee Scientific | $94.9M |
| PDEXPro DEX | $199.3M |
| PLXProtalix BioTherapeutics | $205.5M |
| NATRNatures Sunshine Products | $213.8M |
| Peer median | $83.3M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Harvard Bioscience
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.